Pantoprazole Krka

Pantoprazole, the active ingredient in Pantoprazole Krka, is a proton‑pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Pantoprazole Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is a proton‑pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions: - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: accelerates healing of erosive lesions in the oesophagus. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumours. - Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and reduces recurrence risk.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools, usually transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhoea. - Acute interstitial nephritis: kidney inflammation that may cause reduced urine output. - Severe hypersensitivity reactions: rash, itching, swelling, or anaphylaxis. - Osteoporosis‑related fractures: increased risk of hip, spine or wrist fractures with long‑term use. - Vitamin B12 deficiency: reduced absorption leading to anemia. - Liver enzyme elevation: increased ALT/AST levels indicating hepatic stress.

Before initiating Pantoprazole therapy, consider the following safety measures: - Assess renal function: adjust use in patients with severe impairment. - Review hepatic status: use cautiously in moderate to severe liver disease. - Evaluate need for long‑term therapy: weigh benefits against risks of bone fracture and nutrient deficiencies. - Monitor for infections: be alert for signs of Clostridioides difficile or pneumonia. - Pregnancy and lactation: prescribe only if clearly needed, after risk‑benefit assessment. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several co‑administered medicines. Awareness of these interactions helps maintain therapeutic effectiveness.

Major Interactions (Avoid): - Ketoconazole oral suspension: markedly reduced absorption; avoid concurrent use. - Atazanavir: decreased plasma concentrations; contraindicated in HIV therapy. - Clopidogrel: reduced activation leading to diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR; monitor coagulation parameters. - Digoxin: slight increase in serum levels; observe for toxicity signs. - Methotrexate (high dose): possible accumulation; check renal function and drug levels.